Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging episode artwork

EPISODE · Nov 23, 2025 · 55 MIN

Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging

from Progress, Potential, and Possibilities Podcast / Show · host Ira Pastor / Dr. Carina Kern

Send us Fan MailDr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ),  an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI. Dr. Kern’s labs are based at the Babraham Research Campus, affiliated with the University of Cambridge and her research has led to the development of a first-in-class necrosis inhibitor targeting cellular degeneration (Anti-Necrotic™). This novel therapeutic is ready to begin Phase II clinical trials later this year, as a potential breakthrough treatment for aging, with UK Government, Francis Crick Institute KQ labs, and European Union (Horizon) support. The Anti-Necrotic™ has also been selected as one of only 12 global innovations for NASA’s Space-Health program, recognizing its potential to mitigate accelerated aging in astronauts on long-duration space missions. Dr. Kern has held academic and leadership roles in interdisciplinary networks, including serving as President of the London Evolutionary Research Network and Co-Chair of the CleanTech Business Challenge, an initiative co-led by University College London and the London Business School.Dr. Kern completed her PhD at UCL Institute of Healthy Ageing.#CarinaKern #LinkGevity #BlueprintTheoryOfAging #BiologicalResilience #UniversityOfCambridge #BabrahamResearchCampus #CellularDegeneration #NecrosisInhibitor #AntiNecrotic #CaenorhabditisElegans #UCLInstituteOfHealthyAgeing #Senescence #Apoptosis #CellDeath #Necroptosis #Pyroptosis #Ferroptosis #PathoPathways #Gerotherapeutics #RyanodineReceptorInhibitors #CellPermeantCalciumChelators #LINK001 #AcuteKidneyInjury #SpaceMedicine #Exposome #Longevity#ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Episode metadata supplied by the publisher feed · Published Nov 23, 2025

Embed this episode

Send us Fan Mail Dr. Carina Kern, Ph.D. is the CEO of LinkGevity ( https://www.linkgevity.com/ ), an AI-powered biotech company driving innovation in drug discovery for aging and resilience loss. Dr. Kern has developed a new Blueprint Theory of Aging, which takes an integrative approach to understanding aging, combining evolutionary theory, genetics, molecular mechanisms and medicine, and is used to structure LinkGevity’s AI. Dr. Kern’s labs are based at the Babraham Resea...

Distinct summary based on available episode metadata or transcript content.

Ready to play

Dr. Carina Kern - CEO, LinkGevity - Necrosis Inhibitors To Pause The Diseases Of Aging

0:00 55:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Progress, Potential, and Possibilities Podcast / Show?

This episode is 55 minutes long.

When was this Progress, Potential, and Possibilities Podcast / Show episode published?

This episode was published on November 23, 2025.

Can I download this Progress, Potential, and Possibilities Podcast / Show episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!